During the last session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 2.56 million, with the beta value of the company hitting 1.27. At the end of the trading day, the stock’s price was $3.84, reflecting an intraday gain of 4.63% or $0.17. The 52-week high for the NKTR share is $19.37, that puts it down -404.43 from that peak though still a striking 21.35% gain since the share price plummeted to a 52-week low of $3.02. The company’s market capitalization is $667.85M, and the average intraday trading volume over the past 10 days was 2.82 million shares, and the average trade volume was 3.71 million shares over the past three months.
Nektar Therapeutics (NKTR) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 3.00. NKTR has a Sell rating from 1 analyst(s) out of 13 analysts who have looked at this stock. 10 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.94.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Nektar Therapeutics (NKTR) registered a 4.63% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.63% in intraday trading to $3.84 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 17.43%, and it has moved by -1.03% in 30 days. Based on these gigs, the overall price performance for the year is -76.96%. The short interest in Nektar Therapeutics (NASDAQ:NKTR) is 17.86 million shares and it means that shorts have 5.73 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.70, which implies an increase of 18.3% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.00 and $6.00 respectively. As a result, NKTR is trading at a discount of -56.25% off the target high and 21.87% off the low.
Nektar Therapeutics (NKTR) estimates and forecasts
Statistics show that Nektar Therapeutics has outperformed its competitors in share price, compared to the industry in which it operates. Nektar Therapeutics (NKTR) shares have gone down -73.82% during the last six months, with a year-to-date growth rate more than the industry average at 19.23% against 11.30. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -36.20% this quarter and then jump 40.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -9.20% compared to the previous financial year.
Revenue for the current quarter is expected to be $22.66 million as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to $22.71 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $28.33 million and $24.92 million respectively. In this case, analysts expect current quarter sales to shrink by -20.00% and then drop by -8.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.00%. While earnings are projected to return -14.80% in 2022, the next five years will return -7.30% per annum.
Nektar Therapeutics is due to release its next quarterly earnings between August 03 and August 08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Nektar Therapeutics insiders own 1.11% of total outstanding shares while institutional holders control 95.57%, with the float percentage being 96.64%. Invesco Ltd. is the largest shareholder of the company, while 329 institutions own stock in it. As of Mar 30, 2022, the company held over 37.23 million shares (or 19.99% of all shares), a total value of $200.67 million in shares.
The next largest institutional holding, with 26.11 million shares, is of Blackrock Inc.’s that is approximately 14.02% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $140.76 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nektar Therapeutics (NKTR) shares are Invesco Global Opportunities Fund and iShares Core S&P Smallcap ETF. Data provided on Jan 30, 2022 indicates that Invesco Global Opportunities Fund owns about 35.77 million shares. This amounts to just over 19.20 percent of the company’s overall shares, with a $397.76 million market value. The same data shows that the other fund manager holds slightly less at 13.23 million, or about 7.10% of the stock, which is worth about $54.62 million.